You are here:

Valsartan/hydrochlorothiazide (Co-Diovan®)


Following a full submission.

Valsartan/hydrochlorothiazide (Co-Diovan®) is accepted for use within NHS Scotland for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on valsartan monotherapy.

No increased costs are associated with this product compared with valsartan (Diovan®) alone. Angiotensin receptor blockers are an alternative to ACE inhibitors where these are not tolerated. This fixed dose combination is one of many options for the treatment of hypertension, including other angiotensin receptor blocker/diuretic combinations, many of which are less expensive.

Drug Details

Drug Name: Valsartan/hydrochlorothiazide (Co-Diovan®)
SMC Drug ID: 121/04
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Hypertension
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 September 2004